August 30, 2024
in situ hybridization (ISH) is a technique that enables the localization of specific DNA or RNA sequences within tissue sections and cytology samples using labeled complementary strands. The target gene can be visualized through brightfield or fluorescence microscopy. Compared to immunohistochemistry (IHC), which broadly localizes proteins within tissues, ISH offers greater sensitivity, allowing researchers to understand the organization and function of genes in tissue sections. ISH not only identifies cells positive for a specific DNA/RNA sequence but also quantifies the level of positivity within individual cells.
ISH is a powerful tool in both preclinical research and clinical trials, offering critical insights. It can be combined with IHC assays to provide unique perspectives on cellular and molecular mechanisms within tissues.
Key applications include:
Successful ISH assays depend on meticulous sample preparation to minimize RNA degradation in tissue.
Another crucial aspect for a successful ISH assay is optimization. Each unique combination of species, tissue type, and gene target must be optimized to hone in on the ideal conditions for detecting and visualizing the target. Pre-existing IHC data can guide the optimization process.
Additionally, digital whole slide imaging settings must be tailored to each sample set, accounting for tissue type differences, stain intensity, and autofluorescence.
Consistency in applying the ISH protocol across samples is key. Automated technologies, like the Leica BondRX and Ventana Discovery Ultra, ensure precise and consistent application, minimizing human error.
The integration of AI-powered algorithms with digital whole slide ISH images enhances the analysis, generating data and insights beyond human capability. However, several key steps ensure successful ISH assays.
Our AI-powered algorithms ensure optimal nuclear segmentation for the most reliable results.
Rest assured that our in-house team of pathologists work in proximity with our imaging specialists to ensure you get optimized data from your ISH assays, that signal is neither undercounted nor overestimated.
By leveraging cutting-edge ISH technologies, CellCarta ensures comprehensive and high-quality results for your research and diagnostic needs.
Contact us to get your project started.
Our expert:
Sofie Van Rossom (PhD) is a scientific matter expert for ISH technologies within CellCarta. With a background is Biochemistry & Biotechnology, and many years of experience in the development and validation of new (F)ISH assays to identify DNA and RNA biomarkers of clinical utility, Sofie uses her expertise to guide customers in the validation of their (F)ISH assays.
Posters
November 7, 2024
Histopathology
More infoBrochures & Infographics
October 10, 2024
Histopathology
More infoCellTalk Blog
September 4, 2024
Histopathology
More infoScientific Publications
August 5, 2024
Histopathology
More info